The DAPA Trial in the Context of Previous Prophylactic ICD Landmark Trials

Area of Science:

• Cardiology
• Cardiac Electrophysiology
• Medical Imaging

Background:

• Ischaemic cardiomyopathy with reduced left ventricular ejection fraction (LVEF) creates an arrhythmogenic environment, increasing sudden cardiac death (SCD) risk.
• Current SCD risk stratification models post-primary percutaneous coronary intervention (PCI) are inadequate, necessitating refinement of existing criteria (e.g., LVEF ≤35%).

Purpose of the Study:

• To review the Defibrillator After Primary Angioplasty (DAPA) trial findings.
• To explore the role of left ventricular function post-primary PCI as an early SCD risk marker.
• To assess the impact of prophylactic implantable cardioverter-defibrillator (ICD) implantation on survival.

Main Methods:

• Review of the Defibrillator After Primary Angioplasty (DAPA) trial results.
• Analysis of left ventricular function as a risk marker in ST-elevation myocardial infarction (STEMI) patients treated with acute PCI.
• Evaluation of prophylactic ICD implantation outcomes.

Main Results:

• The DAPA trial provides novel perspectives on left ventricular function as an early SCD risk marker post-primary PCI.
• The trial highlights the impact of prophylactic ICD implantation on survival in this specific patient cohort.
• DAPA was the first trial exclusively including STEMI patients treated with acute PCI for primary prevention analysis.

Conclusions:

• Left ventricular function post-primary PCI is a crucial early risk marker for SCD.
• Prophylactic ICD implantation may improve survival in selected patients with ischaemic cardiomyopathy after acute PCI.
• Further refinement of SCD risk assessment criteria is essential for primary prevention strategies.